# Paclitaxel-bevacizumab in Advanced Lung Cancer

> **NCT01763671** · PHASE3 · COMPLETED · sponsor: **Intergroupe Francophone de Cancerologie Thoracique** · enrollment: 166 (actual)

## Conditions studied

- Non-squamous Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Paclitaxel
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01763671
- **Lead sponsor:** Intergroupe Francophone de Cancerologie Thoracique
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2015-12
- **Final completion:** 2017-04
- **Target enrollment:** 166 (ACTUAL)
- **Last updated:** 2023-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01763671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01763671, "Paclitaxel-bevacizumab in Advanced Lung Cancer". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT01763671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*